Multi Drug Resistant Antibiotics Market Size, Share, Growth, Trends, and Global Industry Analysis: By Type of Bacteria (Multi Drug Resistant Enterococci, Multi-Drug Resistant Staphylococci, Gram Negatives, Others), By Disease (Drug-Resistant Tuberculosis, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others) and Region

Multi-drug resistant antibiotics market size was valued at US$ 10.30 billion in 2023 and is poised to grow at a CAGR of 7.2% from 2024-2030. The multidrug-resistant antibiotics market is driven by the increase in the prevalence of drug-resistant bacterial infections such as multi-drug-resistant TB. In addition, an increase in R&D activities to develop the new generation of multi-drug resistant antibiotics by the marketers coupled with the government and non-government organizations' initiatives and funding are expected to boost the market growth over the forecast period. Furthermore, recent drug resistance antibiotic approvals and promising pipeline drugs are expected to bolster the antibiotic resistance market over the forecast period.

However, high cost of R&D and lack of effective antibiotics are expected to hamper the market multi-drug resistance antibiotics market during the forecast period. Since the discovery of penicillin in 1928, a large number of antibiotics have been used for human therapy, as well as for farm animals and even for fish in aquaculture, resulting in the selection of pathogenic bacteria resistant to multiple drugs. This multidrug resistance may be generated by two mechanisms. One is bacteria may accumulate multiple genes, each coding for resistance to the single drug, within a single cell. Another mechanism is increased gene expressions that code for multidrug efflux pumps, which affect a wide range of drugs. Multi-drug resistant bacteria are formed due to the excessive use of antibiotics in various applications such as prophylactic use for surgery, or immunocompromised patients and other applications. Multi-drug resistant antibiotics are the new generation antibiotics that fight against the drug-resistant bacteria.

Key Developments

• In August 2017, U.S. FDA approved The Medicines Company abomere (meropenem and vaborbactam) for adult patients with urinary tract infections, including pyelonephritis. Vabomere also inhibits certain types of resistance mechanisms used by bacteria.
• In May 2014, U.S. FDA approved Durata Therapeutic  (acquired by Actavis) Dalvance (dalbavancin), a new anti-bacterial drug for the methicillin-resistant Staphylococcus aureus (MRSA) infections.